0001140361-22-007672.txt : 20220303 0001140361-22-007672.hdr.sgml : 20220303 20220303161657 ACCESSION NUMBER: 0001140361-22-007672 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20220301 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220303 DATE AS OF CHANGE: 20220303 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BRISTOL MYERS SQUIBB CO CENTRAL INDEX KEY: 0000014272 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 220790350 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-01136 FILM NUMBER: 22708975 BUSINESS ADDRESS: STREET 1: 430 E. 29TH STREET STREET 2: 14 FLOOR CITY: NEW YORK STATE: NY ZIP: 10016 BUSINESS PHONE: 2125464000 MAIL ADDRESS: STREET 1: 430 E. 29TH STREET STREET 2: 14 FLOOR CITY: NEW YORK STATE: NY ZIP: 10016 FORMER COMPANY: FORMER CONFORMED NAME: BRISTOL MYERS CO DATE OF NAME CHANGE: 19891012 8-K 1 ny20002727x7_8k.htm 8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 1, 2022

BRISTOL-MYERS SQUIBB COMPANY
(Exact name of registrant as specified in its charter)

Delaware	001-01136	22-0790350
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(I.R.S Employer Identification No.)

430 E. 29th Street, 14th Floor
New York, NY, 10016
(Address of principal executive offices) (zip code)

Registrant’s telephone number, including area code: (212) 546-4000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.10 Par Value	BMY	New York Stock Exchange
1.000% Notes due 2025	BMY25	New York Stock Exchange
1.750% Notes due 2035	BMY35	New York Stock Exchange
Celgene Contingent Value Rights	CELG RT	New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On March 1, 2022, Bristol-Myers Squibb Company (“Bristol Myers Squibb”) issued a press release announcing the early participation results, upsizing and early settlement of its previously announced cash tender offers (the “Offers”) to purchase notes issued by Bristol Myers Squibb and Celgene Corporation, Bristol Myers Squibb’s wholly owned subsidiary (collectively, the “Offerors”).

On March 2, 2022, the Offerors also issued a press release announcing the accepted amounts and pricing terms of such previously announced Offers.

The Offers are subject to the terms and conditions described in the Offer to Purchase dated February 15, 2022 (as it may be amended or supplemented from time to time), which sets forth a detailed description of the Offers.

Copies of the press releases are attached hereto as Exhibits 99.1 and 99.2 to this Current Report on Form 8-K and incorporated herein in their entirety.

Item 9.01 Financial Statements and Exhibits.

(d)

Exhibits

The following exhibits are included as part of this Current Report on Form 8-K:

Exhibit No.		Description
99.1		Press release of Bristol-Myers Squibb Company dated March 1, 2022.
99.2		Press release of Bristol-Myers Squibb Company dated March 2, 2022.
104		The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).

EXHIBIT INDEX

Exhibit No.		Description
99.1		Press release of Bristol-Myers Squibb Company dated March 1, 2022.
99.2		Press release of Bristol-Myers Squibb Company dated March 2, 2022.
104		The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: March 3, 2022

	BRISTOL-MYERS SQUIBB COMPANY

	By:	/s/ Kimberly M. Jablonski
	Name:	Kimberly M. Jablonski
	Title:	Corporate Secretary

EX-99.1 2 ny20002727x7_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

Bristol Myers Squibb Announces Early Participation Results,

Upsizing and Early Settlement of Tender Offers

(NEW YORK, March 1, 2022) – Bristol-Myers Squibb Company (NYSE: BMY) (“Bristol Myers Squibb”), with its wholly-owned subsidiary Celgene Corporation (“Celgene”) (collectively, the “Offerors”), announced the early participation results, as of 5:00 p.m. (New York City time) on March 1, 2022 (the “Early Tender Deadline”), of the previously announced 22 separate offers to purchase for cash notes issued by the Offerors listed in the tables below. The Offerors also announced that they are increasing the maximum aggregate purchase price of Notes they will accept for purchase from the previously announced amount of up to an aggregate principal amount that would not result in a maximum aggregate purchase price of more than $4,000,000,000 to an amount more fully described herein, and that they are increasing certain of the Pool Maximums (as defined in the Offer to Purchase) in connection therewith (collectively, the “Amended Maximum Acceptance Amounts”). All other terms and conditions of the tender offers as previously announced in the Offer to Purchase, as amended and supplemented hereby, remain unchanged.

The outstanding debt securities listed in (i) the first table below labeled “2025 Pool” are referred to collectively as the “2025 Pool Notes,” (ii) the second table below labeled “2026 Pool” are referred to collectively as the “2026 Pool Notes,” (iii) the third table below labeled “2027 Pool” are referred to collectively as the “2027 Pool Notes,” (iv) the fourth table below labeled “2029 Pool” are referred to collectively as the “2029 Pool Notes,” and (v) the fifth table below labeled “High Coupon Pool” are referred to collectively as the “High Coupon Pool Notes.” The High Coupon Pool Notes, the 2025 Pool Notes, the 2026 Pool Notes, the 2027 Pool Notes and the 2029 Pool Notes are referred to collectively as the “Notes,” and each series of Notes is referred to as a “series.” We refer to each offer to purchase a series of Notes for cash as an “Offer,” the offers to purchase the 2025 Pool Notes collectively as the “2025 Pool Offers,” the offers to purchase the 2026 Pool Notes collectively as the “2026 Pool Offers,” the offers to purchase the 2027 Pool Notes collectively as the “2027 Pool Offers,” the offers to purchase the 2029 Pool Notes collectively as the “2029 Pool Offers,” the offers to purchase the High Coupon Pool Notes collectively as the “High Coupon Pool Offers,” and all the offers to purchase Notes are referred to collectively as the “Offers.”

The Offerors’ obligations to accept Notes tendered in the Offers are subject to the terms and conditions described in the Offer to Purchase dated February 15, 2022 (as it may be amended or supplemented from time to time, the “Offer to Purchase”) which sets forth a detailed description of the Offers, including:

(a) the Acceptance Priority Procedures (as defined in the Offer to Purchase), and (b) the following Amended Maximum Acceptance Amounts:

all of the 2025 Pool Notes tendered as of the Early Tender Deadline, hereby amending the $500 million maximum aggregate purchase price of the 2025 Pool Notes validly tendered in the 2025 Pool Offers previously disclosed in the Offer to Purchase;

ii.

$500 million maximum aggregate principal amount of the 2026 Pool Notes, hereby amending the $500 million maximum aggregate purchase price of the 2026 Pool Notes validly tendered in the 2026 Pool Offers previously disclosed in the Offer to Purchase;

iii.

all of the 2027 Pool Notes tendered as of the Early Tender Deadline, hereby amending the $500 million maximum aggregate purchase price of the 2027 Pool Notes validly tendered in the 2027 Pool Offers previously disclosed in the Offer to Purchase;

iv.

$1.6 billion maximum aggregate principal amount of the 2029 Pool Notes, hereby amending the $1.25 billion maximum aggregate purchase price of the 2029 Pool Notes validly tendered in the 2029 Pool Offers previously disclosed in the Offer to Purchase; and

$1.5 billion maximum aggregate principal amount of the High Coupon Pool Notes, hereby amending the $1.25 billion maximum aggregate purchase price of the High Coupon Pool Notes validly tendered in the High Coupon Pool Offers previously disclosed in the Offer to Purchase.

The Offerors were advised by Global Bondholder Services Corporation, as the tender agent and information agent, that as of the Early Tender Deadline, the aggregate principal amounts of the Notes specified in the tables below were validly tendered and not validly withdrawn:

2025 Pool

Offers to purchase for cash all of the aggregate principal amount tendered as of the Early Tender Deadline of the securities listed in the priority order below.

Acceptance Priority Level	Title of Security	CUSIP Number(s)	Issuer / Offeror	Principal Amount Outstanding	Principal Amount Tendered as of the Early Tender Deadline
1	3.875% Notes due 2025	110122DC9/ 110122BN7/ U11009AN4	Bristol Myers Squibb	$1,822,221,000	$821,877,000
1	3.875% Notes due 2025	151020AS3	Celgene	$103,050,000	$25,355,000

2026 Pool

Offers to purchase for cash up to $500,000,000 aggregate principal amount of the securities listed in the priority order below.

Acceptance Priority Level	Title of Security	CUSIP Number(s)	Issuer / Offeror	Principal Amount Outstanding	Principal Amount Tendered as of the Early Tender Deadline
1	3.200% Notes due 2026	110122CN6/ 110122CA4/ U11009BA1	Bristol Myers Squibb	$2,250,000,000	$1,455,673,000

2027 Pool

Offers to purchase for cash all of the aggregate principal amount tendered as of the Early Tender Deadline of the securities listed in the priority order below.

Acceptance Priority Level	Title of Security	CUSIP Number(s)	Issuer / Offeror	Principal Amount Outstanding	Principal Amount Tendered as of the Early Tender Deadline
1	3.450% Notes due 2027*	110122DD7/ 110122BP2/ U11009AP9	Bristol Myers Squibb	$961,528,000	$443,786,000
1	3.450% Notes due 2027*	151020AY0	Celgene	$38,467,000	$21,919,000
2	3.250% Notes due 2027	110122BB3	Bristol Myers Squibb	$750,000,000	$237,723,000

2029 Pool

Offers to purchase for cash up to $1,600,000,000 aggregate principal amount of the securities listed in the priority order below.

Acceptance Priority Level	Title of Security	CUSIP Number(s)	Issuer / Offeror	Principal Amount Outstanding	Principal Amount Tendered as of the Early Tender Deadline
1	3.400% Notes due 2029*	110122CP1/ 110122CB2/ U11009BB9	Bristol Myers Squibb	$4,000,000,000	$2,316,845,000

High Coupon Pool

Offers to purchase for cash up to $1,500,000,000 aggregate principal amount of the securities listed in the priority order below.

Acceptance Priority Level	Title of Security	CUSIP Number(s)	Issuer / Offeror	Principal Amount Outstanding	Principal Amount Tendered as of the Early Tender Deadline
1	6.875% Notes due 2097	110122AC2	Bristol Myers Squibb	$85,727,000	$23,310,000
2	5.700% Notes due 2040	110122DF2/ 110122BR8/ U11009AR5	Bristol Myers Squibb	$188,880,000	$37,869,000
2	5.700% Notes due 2040	151020AF1	Celgene	$3,849,000	$1,550,000
3	5.250% Notes due 2043	110122DG0/ 110122BS6/ U11009AS3	Bristol Myers Squibb	$274,303,000	$52,630,000
3	5.250% Notes due 2043	151020AL8	Celgene	$5,890,000	$1,826,000
4	5.000% Notes due 2045*	110122DJ4/ 110122BU1/ U11009AU8	Bristol Myers Squibb	$1,733,461,000	$991,737,000
4	5.000% Notes due 2045*	151020AU8	Celgene	$34,749,000	$19,040,000
5	4.500% Notes due 2044*	110122AX6	Bristol Myers Squibb	$500,000,000	$158,480,000
6	4.550% Notes due 2048*	110122DL9/ 110122BW7/ U11009AW4	Bristol Myers Squibb	$1,447,340,000	$950,533,000
6	4.550% Notes due 2048*	151020AZ7	Celgene	$38,440,000	$5,575,000
7	4.250% Notes due 2049*	110122CR7/ 110122CD8/ U11009BD5	Bristol Myers Squibb	$3,750,000,000	$2,030,240,000
8	4.625% Notes due 2044*	110122DH8/ 110122BT4/ U11009AT1	Bristol Myers Squibb	$744,719,000	$434,446,000
8	4.625% Notes due 2044*	151020AM6	Celgene	$3,691,000	$982,000
9	4.350% Notes due 2047*	110122DK1/ 110122BV9/ U11009AV6	Bristol Myers Squibb	$1,236,433,000	$853,617,000
9	4.350% Notes due 2047*	151020AW4	Celgene	$13,567,000	$7,314,000

Denotes a series of Notes for which the Total Consideration, the Tender Consideration and the Offer Yield (each as defined in the Offer to Purchase) will be determined taking into account the par call date, instead of the maturity date, of the Notes of such series in accordance with standard market practice.

The withdrawal rights for the Offers expired at 5:00 p.m. (New York City time) on March 1, 2022. All conditions of the Offers were deemed satisfied or waived by the Offerors by the Early Tender Deadline. The Offerors have elected to exercise their Early Settlement Right (as defined in the Offer to Purchase). The Early Settlement Date (as defined in the Offer to Purchase) will occur on March 4, 2022. Because the aggregate principal amount of Notes validly tendered and not validly withdrawn at or prior to the Early Tender Deadline met or exceeded the Amended Maximum Acceptance Amounts, the Offerors do not expect to accept for purchase any Notes tendered after the Early Tender Deadline. The Offers will each expire at 11:59 p.m. (New York City time) on March 15, 2022, unless extended or earlier terminated by the Offerors.

Promptly after 9:00 a.m. (New York City time) on March 2, 2021 (the “Price Determination Date”), the Offerors will issue a press release specifying, among other things, (i) the aggregate principal amount of Notes accepted in each Offer, (ii) the offer yield, which is the applicable yield to maturity based on the price of the applicable Reference U.S. Treasury Security for that series as of the Price Determination Date plus the applicable fixed spread (as specified in the Offer to Purchase) (the “Offer Yield”), and (iii) the proration factor (if any) applied to such validly tendered Notes. All Holders of Notes (each, a “Holder” and collectively, “Holders”) whose Notes are accepted in an Offer will receive a cash payment equal to accrued and unpaid interest on such Notes to, but not including, the relevant Settlement Date (as defined in the Offer to Purchase) (the “Accrued Coupon Payment”) in addition to their Total Consideration or Tender Consideration, as applicable. For the avoidance of doubt, interest will cease to accrue on the relevant Settlement Date for all Notes accepted in the Offers. Under no circumstances will any interest be payable to Holders because of any delay on the part of Global Bondholder Services Corporation, as the tender agent and information agent, The Depository Trust Company or any other party in the transmission of funds to Holders. See the Offer to Purchase for additional information.

All Notes accepted in the Offers will be cancelled and retired and will no longer remain outstanding obligations of the relevant Offeror. Following the Price Determination Date, the Offerors may elect to redeem all or a portion of Bristol Myers Squibb’s 3.875% Notes due 2025 or 3.200% Notes due 2026 or Celgene’s 3.875% Notes due 2025 that are not tendered and accepted in the Offers in accordance with the terms of the optional redemption provisions in the indentures governing such Notes.

The Offerors have retained Deutsche Bank Securities Inc., BofA Securities, Inc. and Goldman Sachs & Co. LLC as dealer managers for the Offers. Questions regarding terms and conditions of the Offers should be directed to Deutsche Bank Securities Inc. at (866) 627-0391 (toll-free) or (212) 250-2955 (collect) or BofA Securities, Inc. at (888) 292-0070 (toll-free) or (980) 683-3215 (collect) or Goldman Sachs & Co. LLC at (800) 828-3182 (toll-free) or (212) 902-5962 (collect). Global Bondholder Services Corporation is acting as the tender agent and the information agent for the Offers (the “Tender and Information Agent”).

Offer and Distribution Restrictions

This announcement is for informational purposes only. This announcement is not an offer to sell or purchase, a solicitation of an offer to sell or purchase, or the solicitation of tenders with respect to any of Notes described herein. The Offers are being made solely pursuant to the Offer to Purchase. The Offers are not being made to Holders of Notes in any jurisdiction in which the making or acceptance thereof would not be in compliance with the securities, blue sky or other laws of such jurisdiction. In any jurisdiction in which the securities laws or blue sky laws require the Offers to be made by a licensed broker or dealer, the Offers will be deemed to be made on behalf of the Offerors by the dealer managers or one or more registered brokers or dealers that are licensed under the laws of such jurisdiction.

United Kingdom

The Offer to Purchase is only addressed to Holders where they would (if they were clients of the Offerors) be per se professional clients or per se eligible counterparties of the Offerors within the meaning of the rules of the Financial Conduct Authority (“ FCA ”). Neither the Offer to Purchase nor any other related documents or materials are addressed to or directed at any persons who would be retail clients within the meaning of the FCA rules and any such persons should not act or rely on them. Recipients of the Offer to Purchase and any other documents or materials relating to the Offer should note that the Offerors is acting on its own account in relation to the Tender Offer and will not be responsible to any other person for providing the protections which would be afforded to clients of the Offerors or for providing advice in relation to the Offer.

This announcement, the Offer to Purchase and any other documents or materials relating to the Tender Offer are not being made and such documents have not been approved by an authorized person for the purposes of section 21 of the Financial Services and Markets Act 2000. Accordingly, such documents and/or materials are not being distributed to, and must not be passed on to, the general public in the United Kingdom. The communication of such documents and/or materials as a financial promotion is only being made to persons outside the United Kingdom and to those persons in the United Kingdom falling within the definition of investment professionals (as defined by Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (“ Financial Promotion Order ”)) or persons who are within Article 43 of the Financial Promotion Order or any other persons to whom they may otherwise lawfully be communicated under the Financial Promotion Order and should not be relied on or acted on in the United Kingdom by any other persons.

EEA

In the EEA, this announcement and the Tender Offer will not, directly or indirectly, be made to, or for the account of, any person other than to qualified investors within the meaning of Article 2(e) of the Prospectus Regulation. Neither this announcement nor the Offer to Purchase, nor any other documentation or material relating to the Tender Offer, has been or will be submitted to a competent authority in the EEA for approval. Therefore, neither the Offer to Purchase nor any other documentation or material relating to the Tender Offer qualifies as an approved prospectus as meant in Article 6 of the Prospectus Regulation.

Accordingly, in the EEA, the Tender Offer may not be made by way of an “offer of securities to the public” within the meaning of Article 2(d) of the Prospectus Regulation and the Offer may not be promoted and is not being made to, any person in the EEA (with the exception of “qualified investors” within the meaning of Article 2(e) in conjunction with Article 1(4)(a) of the Prospectus Regulation). This announcement, the Offer to Purchase and any other documentation or materials relating to the Tender Offer (including memoranda, information circulars, brochures or similar documents) have not been forwarded or made available to, and are not being forwarded or made available to, directly or indirectly, any such person.

With regard to the EEA, this announcement and the Offer to Purchase have been transmitted only for personal use by the aforementioned qualified investors and only for the purpose of the Tender Offer. Accordingly, the information contained in this announcement and the Offer to Purchase may not be used for any other purpose or be transmitted to any other person in the EEA.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains certain “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). You can identify these forward-looking statements by the fact they use words such as “should,” “could,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe,” “will” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance, although not all forward-looking statements contain such terms. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. These statements are likely to relate to, among other things, Bristol Myers Squibb’s goals, plans and objectives regarding its financial position, results of operations, cash flows, market position, product development, product approvals, sales efforts, expenses, performance or results of current and anticipated products, its business development strategy and capital allocation strategy, its ability to realize the projected benefits of its acquisitions of Celgene and MyoKardia, Inc., the full extent of the impact of the coronavirus disease (“COVID-19”) pandemic on its operations and the development and commercialization of its products, potential laws and regulations to lower drug costs, market actions taken by private and government payers to manage drug utilization and contain costs, the expiration of patents or data protection on certain products, including assumptions about its ability to retain patent exclusivity of certain products, and the impact and the result of governmental investigations. No forward-looking statement can be guaranteed.

Forward-looking statements are based on current expectations and projections about Bristol Myers Squibb’s future financial results, goals, plans and objectives and involve inherent risks, assumptions and uncertainties, including internal or external factors that could delay, divert or change any of them in the next several years, that are difficult to predict, may be beyond its control and could cause its future financial results, goals, plans and objectives to differ materially from those expressed in, or implied by, the statements. Such risks, uncertainties and other matters include, but are not limited to: increasing pricing pressures from market access, pharmaceutical pricing controls and discounting; changes to tax and importation laws and other restrictions in the United States, the European Union and other regions around the world that result in lower prices, lower reimbursement rates and smaller populations for whom payers will reimburse; changes under the 340B Drug Pricing Program; challenges inherent in new product development, including obtaining and maintaining regulatory approval; its ability to obtain and protect market exclusivity rights and enforce patents and other intellectual property rights; the possibility of difficulties and delays in product introduction and commercialization; the risk of certain novel approaches to disease treatment (such as CAR T therapy); industry competition from other manufacturers; potential difficulties, delays and disruptions in manufacturing, distribution or sale of products, including without limitation, interruptions caused by damage to its and its suppliers’ manufacturing sites; the impact of integrating its and Celgene’s business and operations, including with respect to human capital management, portfolio rationalization, finance and accounting systems, sales operations and product distribution, pricing systems and methodologies, data security systems, compliance programs and internal controls processes; the risk of an adverse patent litigation decision or settlement and exposure to other litigation and/or regulatory actions; the impact of any healthcare reform and legislation or regulatory action in the United States and international markets; increasing market penetration of lower-priced generic products; the failure of its suppliers, vendors, outsourcing partners, alliance partners and other third parties to meet their contractual, regulatory and other obligations; regulatory decisions impacting labeling, manufacturing processes and/or other matters; the impact on its competitive position from counterfeit or unregistered versions of its products or stolen products; the adverse impact of cyber-attacks on its information systems or products, including unauthorized disclosure of trade secrets or other confidential data stored in its information systems and networks; its ability to execute its financial, strategic and operational plans; its ability to identify potential strategic acquisitions, licensing opportunities or other beneficial transactions; its dependency on several key products; any decline in its future royalty streams; its ability to effectively manage acquisitions, divestitures, alliances and other portfolio actions and to successfully realize the expected benefits of such actions; its ability to attract and retain key personnel; the impact of its significant additional indebtedness that it incurred in connection with the Celgene acquisition and the MyoKardia acquisition; political and financial instability of international economies and sovereign risk; interest rate and currency exchange rate fluctuations, credit and foreign exchange risk management; the impact of adverse outcomes in lawsuits, claims, proceedings and government investigations; issuance of new or revised accounting standards; and risks relating to public health outbreaks, epidemics and pandemics, including the impact of the COVID-19 pandemic on its operations.

The foregoing list sets forth some, but not all, of the factors that could have an impact upon Bristol Myers Squibb’s ability to achieve results described in any forward-looking statements. In addition, all of the forward-looking statements that it makes in this document are qualified by the information incorporated by reference into this press release, including, but not limited to (i) the information contained under this heading and (ii) the information discussed under the sections entitled “Risk Factors” in its Annual Report on Form 10-K for the year ended December 31, 2021, as updated by the risk factors discussed in its future filings with the SEC. See “Where You Can Find More Information; Documents Incorporated by Reference.”

Persons reading this press release are cautioned not to place undue reliance on Bristol Myers Squibb’s forward-looking statements. These forward-looking statements are and will be based upon management’s then-current views and assumptions regarding future events and operating performance and are applicable only as of the dates of such statements. You also should understand that it is not possible to predict or identify all such factors and that this list should not be considered a complete statement of all potential risks and uncertainties. Investors also should realize that if underlying assumptions prove inaccurate or if unknown risks or uncertainties materialize, actual results could vary materially from its projections. Except as otherwise required by law, it is not under any obligation, and expressly disclaim any obligation, to update, alter, or otherwise revise any forward-looking statements included in this press release, or elsewhere, whether written or oral, that may be made from time to time relating to any of the matters discussed in this press release, whether as a result of new information, future events, changed circumstances or otherwise, as of any future date.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram.

###

For more information, contact:

Media: media@bms.com

Investor Relations: Investor.Relations@bms.com

EX-99.2 3 ny20002727x7_ex99-2.htm EXHIBIT 99.2

Exhibit 99.2

Bristol Myers Squibb Announces Accepted Amounts and Pricing Terms of its Tender Offers

(NEW YORK, March 2, 2022) – Bristol-Myers Squibb Company (NYSE:BMY) (“Bristol Myers Squibb”), with its wholly-owned subsidiary Celgene Corporation (“Celgene”) (collectively, the “Offerors”), announced the accepted amounts and pricing terms of their previously announced 22 separate offers to purchase for cash notes issued by the Offerors listed in the tables listed herein.

The table below indicates, among other things, the aggregate principal amount of Notes tendered as of 5:00 p.m. (New York City time) on March 1, 2022 (the “Early Tender Deadline”) and accepted in each Offer, the Offer Yield (each as defined below), the proration factor, if any, and the total consideration for each $1,000 principal amount of each series of Notes validly tendered at or prior to the Early Tender Deadline and accepted for purchase (the “Total Consideration”), as calculated at 9:00 a.m. (New York City time) today, March 2, 2022 in accordance with the terms of the Offer to Purchase dated February 15, 2022 (as it may be amended or supplemented from time to time, the “Offer to Purchase”), as amended by Bristol Myers Squibb’s press release dated March 1, 2022:

2025 Pool

Offers to purchase for cash all of the aggregate principal amount tendered as of the Early Tender Deadline of the securities listed in the priority order below.

Acceptance Priority Level	Title of Security	CUSIP Number(s)	Issuer / Offeror	Principal Amount Outstanding	Principal Amount Tendered as of the Early Tender Deadline	Principal Amount Accepted	Offer Yield⁽¹⁾	Approximate Proration Factor	Total Consideration⁽²⁾
1	3.875% Notes due 2025	110122DC9/ 110122BN7/ U11009AN4	Bristol Myers Squibb	$1,822,221,000	$821,877,000	$821,877,000	1.961%	100%	$1,063.49
1	3.875% Notes due 2025	151020AS3	Celgene	$103,050,000	$25,355,000	$25,355,000	1.961%	100%	$1,063.49

2026 Pool

Offers to purchase for cash up to $500,000,000 aggregate principal amount of the securities listed in the priority order below.

Acceptance Priority Level	Title of Security	CUSIP Number(s)	Issuer / Offeror	Principal Amount Outstanding	Principal Amount Tendered as of the Early Tender Deadline	Principal Amount Accepted	Offer Yield⁽¹⁾	Approximate Proration Factor	Total Consideration⁽²⁾
1	3.200% Notes due 2026	110122CN6/ 110122CA4/ U11009BA1	Bristol Myers Squibb	$2,250,000,000	$1,455,673,000	$500,002,000	1.842%	34.38%	$1,055.63

2027 Pool

Offers to purchase for cash all of the aggregate principal amount tendered as of the Early Tender Deadline of the securities listed in the priority order below.

Acceptance Priority Level	Title of Security	CUSIP Number(s)	Issuer / Offeror	Principal Amount Outstanding	Principal Amount Tendered as of the Early Tender Deadline	Principal Amount Accepted	Offer Yield⁽¹⁾	Approximate Proration Factor	Total Consideration⁽²⁾
1	3.450% Notes due 2027*	110122DD7/ 110122BP2/ U11009AP9	Bristol Myers Squibb	$961,528,000	$443,786,000	$443,786,000	2.135%	100%	$1,067.28
1	3.450% Notes due 2027*	151020AY0	Celgene	$38,467,000	$21,919,000	$21,919,000	2.135%	100%	$1,067.28
2	3.250% Notes due 2027	110122BB3	Bristol Myers Squibb	$750,000,000	$237,723,000	$237,723,000	2.085%	100%	$1,054.84

2029 Pool

Offers to purchase for cash up to $1,600,000,000 aggregate principal amount of the securities listed in the priority order below.

Acceptance Priority Level	Title of Security	CUSIP Number(s)	Issuer / Offeror	Principal Amount Outstanding	Principal Amount Tendered as of the Early Tender Deadline	Principal Amount Accepted	Offer Yield⁽¹⁾	Approximate Proration Factor	Total Consideration⁽²⁾
1	3.400% Notes due 2029*	110122CP1/ 110122CB2/ U11009BB9	Bristol Myers Squibb	$4,000,000,000	$2,316,845,000	$1,600,023,000	2.356%	69.09%	$1,068.28

High Coupon Pool

Offers to purchase for cash up to $1,500,000,000 aggregate principal amount of the securities listed in the priority order below.

Acceptance Priority Level	Title of Security	CUSIP Number(s)	Issuer / Offeror	Principal Amount Outstanding	Principal Amount Tendered as of the Early Tender Deadline	Principal Amount Accepted	Offer Yield⁽¹⁾	Approximate Proration Factor	Total Consideration⁽²⁾
1	6.875% Notes due 2097	110122AC2	Bristol Myers Squibb	$85,727,000	$23,310,000	$23,310,000	4.122%	100%	$1,637.03
2	5.700% Notes due 2040	110122DF2/ 110122BR8/ U11009AR5	Bristol Myers Squibb	$188,880,000	$37,869,000	$37,869,000	3.526%	100%	$1,294.84
2	5.700% Notes due 2040	151020AF1	Celgene	$3,849,000	$1,550,000	$1,550,000	3.526%	100%	$1,294.84
3	5.250% Notes due 2043	110122DG0/ 110122BS6/ U11009AS3	Bristol Myers Squibb	$274,303,000	$52,630,000	$52,630,000	3.526%	100%	$1,257.88
3	5.250% Notes due 2043	151020AL8	Celgene	$5,890,000	$1,826,000	$1,826,000	3.526%	100%	$1,257.88
4	5.000% Notes due 2045*	110122DJ4/ 110122BU1/ U11009AU8	Bristol Myers Squibb	$1,733,461,000	$991,737,000	$991,737,000	3.396%	100%	$1,254.21
4	5.000% Notes due 2045*	151020AU8	Celgene	$34,749,000	$19,040,000	$19,040,000	3.396%	100%	$1,254.21
5	4.500% Notes due 2044*	110122AX6	Bristol Myers Squibb	$500,000,000	$158,480,000	$158,480,000	3.316%	100%	$1,180.95
6	4.550% Notes due 2048*	110122DL9/ 110122BW7/ U11009AW4	Bristol Myers Squibb	$1,447,340,000	$950,533,000	$212,332,000	3.352%	22.38%	$1,204.07
6	4.550% Notes due 2048*	151020AZ7	Celgene	$38,440,000	$5,575,000	$1,236,000	3.352%	22.38%	$1,204.07
7	4.250% Notes due 2049*	110122CR7/ 110122CD8/ U11009BD5	Bristol Myers Squibb	$3,750,000,000	$2,030,240,000	—	—	—	—
8	4.625% Notes due 2044*	110122DH8/ 110122BT4/ U11009AT1	Bristol Myers Squibb	$744,719,000	$434,446,000	—	—	—	—
8	4.625% Notes due 2044*	151020AM6	Celgene	$3,691,000	$982,000	—	—	—	—
9	4.350% Notes due 2047*	110122DK1/ 110122BV9/ U11009AV6	Bristol Myers Squibb	$1,236,433,000	$853,617,000	—	—	—	—
9	4.350% Notes due 2047*	151020AW4	Celgene	$13,567,000	$7,314,000	—	—	—	—

(1)

The “Offer Yield” is equal to the applicable Reference Yield (as defined in the Offer to Purchase), which is based on the bid-side price of the applicable Reference U.S. Treasury Security (as specified in the Offer to Purchase)) plus the applicable Fixed Spread (as specified in the Offer to Purchase).

(2)	Includes the Early Tender Premium (as defined in the Offer to Purchase). Payable per each $1,000 principal amount of each specified series of Notes validly tendered at or prior to the Early Tender Deadline and accepted for purchase.

Denotes a series of Notes for which the Total Consideration, the Tender Consideration (as defined in the Offer to Purchase), and the Offer Yield were determined taking into account the par call date, instead of the maturity date, of the Notes of such series in accordance with standard market practice.

The Offerors’ obligations to accept Notes tendered in the Offers are subject to the terms and conditions described in the Offer to Purchase, as amended by Bristol Myers Squibb’s press release dated March 1, 2022, which sets forth a detailed description of the Offers, including: (a) the Acceptance Priority Procedures (as defined in the Offer to Purchase), and (b) the following Amended Maximum Acceptance Amounts (as defined in the Offer to Purchase):

all of the 2025 Pool Notes tendered as of the Early Tender Deadline (the “2025 Pool Maximum”);

ii.

$500 million maximum aggregate principal amount of the 2026 Pool Notes (the “2026 Pool Maximum”);

iii.

all of the 2027 Pool Notes tendered as of the Early Tender Deadline (the “2027 Pool Maximum”);

iv.

$1.6 billion maximum aggregate principal amount of the 2029 Pool Notes (the “2029 Pool Maximum”); and

$1.5 billion maximum aggregate principal amount of the High Coupon Pool Notes (the “High Coupon Pool Maximum”).

The withdrawal rights for the Offers expired at 5:00 p.m. (New York City time) on March 1, 2022. The Offers will each expire at 11:59 p.m. (New York City time) on March 15, 2022, unless extended or earlier terminated by the Offerors (such date and time with respect to an Offer, as the same may be extended with respect to such Offer, the “Expiration Date”).

The withdrawal rights for the Offers expired at 5:00 p.m. (New York City time) on March 1, 2022. As previously announced, all conditions of the Offers were deemed satisfied or waived by the Offerors by the Early Tender Deadline. As previously announced, the Offerors have elected to exercise their Early Settlement Right (as defined in the Offer to Purchase). The Early Settlement Date (as defined in the Offer to Purchase) will occur on March 4, 2022.

Since the aggregate principal amount of the 2025 Pool Notes, 2026 Pool Notes, 2027 Pool Notes, 2029 Pool Notes, and High Coupon Pool Notes validly tendered and not validly withdrawn at or prior to the Early Tender Deadline meets or exceeds the 2025 Pool Maximum, 2026 Pool Maximum, 2027 Pool Maximum, 2029 Pool Maximum, or High Coupon Pool Maximum, as applicable, the Offerors will accept such Notes for purchase according to the Acceptance Priority Procedures and proration steps as described in the Offer to Purchase. Holders of Notes (each, a “Holder” and collectively, “Holders”) validly tendered at or prior to the Early Tender Deadline that are accepted for purchase by the Offerors will receive the applicable Total Consideration, in cash. Because the aggregate principal amount of Notes validly tendered and not validly withdrawn at or prior to the Early Tender Deadline exceeded the Amended Maximum Acceptance Amounts, there will be no Final Settlement Date (as defined in the Offer to Purchase) and no additional tenders of Notes will be accepted for purchase by the Offerors after the Early Tender Deadline. As described in the Offer to Purchase, Notes tendered and not accepted for purchase will be promptly returned to the tendering Holder’s account.

The Total Consideration that will be paid on the Early Tender Deadline for each series of notes accepted for purchase does not include a cash payment equal to accrued and unpaid interest (the “Accrued Coupon Payment”) on such Notes to, but not including, the Early Settlement Date. For the avoidance of doubt, interest will cease to accrue on the Early Settlement Date for all Notes accepted in the Offers. Under no circumstances will any interest be payable to Holders because of any delay on the part of Global Bondholder Services Corporation, as the tender agent and information agent, The Depository Trust Company or any other party in the transmission of funds to Holders. See the Offer to Purchase for additional information.

All Notes accepted in the Offers will be cancelled and retired and will no longer remain outstanding obligations of the relevant Offeror. Following the Price Determination Date (as defined in the Offer to Purchase), the Offerors may elect to redeem all or a portion of Bristol Myers Squibb’s 3.875% Notes due 2025 or 3.200% Notes due 2026 or Celgene’s 3.875% Notes due 2025 that are not tendered and accepted in the Offers in accordance with the terms of the optional redemption provisions in the indentures governing such Notes.

Offer and Distribution Restrictions

United Kingdom

EEA

Cautionary Statement Regarding Forward-Looking Statements

About Bristol Myers Squibb

###

For more information, contact:

Media: media@bms.com

Investor Relations: Investor.Relations@bms.com

EX-101.SCH 4 bmy-20220301.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 5 bmy-20220301_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 6 bmy-20220301_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Class of Stock [Domain] Common Stock [Member] Class of Stock [Axis] Cover [Abstract] Document Type Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Emerging Growth Company Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number Entity Listings [Table] Entity Listings [Line Items] Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name 1.000% Notes due 2025 [Member] 1.750% Notes due 2035 [Member] Celgene Contingent Value Rights [Member] EX-101.PRE 7 bmy-20220301_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 8 ny20002727x7_logo01.jpg begin 644 ny20002727x7_logo01.jpg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htm IDEA: XBRL DOCUMENT

Document and Entity Information	Mar. 01, 2022
Entity Listings [Line Items]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Mar. 01, 2022
Entity Registrant Name	BRISTOL-MYERS SQUIBB COMPANY
Entity Incorporation, State or Country Code	DE
Entity File Number	001-01136
Entity Tax Identification Number	22-0790350
Entity Address, Address Line One	430 E. 29th Street
Entity Address, Address Line Two	14th Floor
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10016
City Area Code	212
Local Phone Number	546-4000
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Entity Emerging Growth Company	false
Entity Central Index Key	0000014272
Common Stock [Member]
Entity Listings [Line Items]
Title of 12(b) Security	Common Stock, $0.10 Par Value
Trading Symbol	BMY
Security Exchange Name	NYSE
1.000% Notes due 2025 [Member]
Entity Listings [Line Items]
Title of 12(b) Security	1.000% Notes due 2025
Trading Symbol	BMY25
Security Exchange Name	NYSE
1.750% Notes due 2035 [Member]
Entity Listings [Line Items]
Title of 12(b) Security	1.750% Notes due 2035
Trading Symbol	BMY35
Security Exchange Name	NYSE
Celgene Contingent Value Rights [Member]
Entity Listings [Line Items]
Title of 12(b) Security	Celgene Contingent Value Rights
Trading Symbol	CELG RT
Security Exchange Name	NYSE

XML 10 ny20002727x7_8k_htm.xml IDEA: XBRL DOCUMENT 0000014272 2022-03-01 2022-03-01 0000014272 us-gaap:CommonStockMember 2022-03-01 2022-03-01 0000014272 bmy:One000NotesDue2025Member 2022-03-01 2022-03-01 0000014272 bmy:One750NotesDue2035Member 2022-03-01 2022-03-01 0000014272 bmy:CelgeneContingentValueRightsMember 2022-03-01 2022-03-01 false 0000014272 8-K 2022-03-01 BRISTOL-MYERS SQUIBB COMPANY DE 001-01136 22-0790350 430 E. 29th Street 14th Floor New York NY 10016 212 546-4000 false false false false Common Stock, $0.10 Par Value BMY NYSE 1.000% Notes due 2025 BMY25 NYSE 1.750% Notes due 2035 BMY35 NYSE Celgene Contingent Value Rights CELG RT NYSE false EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.0.1 html 5 118 1 false 4 0 false 0 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://bms.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports ny20002727x7_8k.htm bmy-20220301.xsd bmy-20220301_def.xml bmy-20220301_lab.xml bmy-20220301_pre.xml ny20002727x7_ex99-1.htm ny20002727x7_ex99-2.htm http://xbrl.sec.gov/dei/2021 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ny20002727x7_8k.htm": { "axisCustom": 0, "axisStandard": 1, "contextCount": 5, "dts": { "definitionLink": { "local": [ "bmy-20220301_def.xml" ] }, "inline": { "local": [ "ny20002727x7_8k.htm" ] }, "labelLink": { "local": [ "bmy-20220301_lab.xml" ] }, "presentationLink": { "local": [ "bmy-20220301_pre.xml" ] }, "schema": { "local": [ "bmy-20220301.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" ] } }, "elementCount": 37, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 118, "memberCustom": 3, "memberStandard": 1, "nsprefix": "bmy", "nsuri": "http://bms.com/20220301", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ny20002727x7_8k.htm", "contextRef": "c20220301to20220301", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000100 - Document - Document and Entity Information", "role": "http://bms.com/role/DocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ny20002727x7_8k.htm", "contextRef": "c20220301to20220301", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 4, "tag": { "bmy_CelgeneContingentValueRightsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Celgene Contingent Value Rights [Member]" } } }, "localname": "CelgeneContingentValueRightsMember", "nsuri": "http://bms.com/20220301", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "bmy_One000NotesDue2025Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "1.000% Notes due 2025 [Member]" } } }, "localname": "One000NotesDue2025Member", "nsuri": "http://bms.com/20220301", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "bmy_One750NotesDue2035Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "1.750% Notes due 2035 [Member]" } } }, "localname": "One750NotesDue2035Member", "nsuri": "http://bms.com/20220301", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityListingsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Entity Listings [Line Items]" } } }, "localname": "EntityListingsLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_EntityListingsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container for exchange listing information for an entity", "label": "Entity Listings [Table]" } } }, "localname": "EntityListingsTable", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 17 0001140361-22-007672-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140361-22-007672-xbrl.zip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�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